

Supplementary Table S1. Clinicopathological characteristics in relation to POLD1 expression level in the TCGA cohort.

Characteristics	Patients	POLD1 expression		χ^2	P value
		Low (%)	High (%)		
Age				0.236	0.627
<= 60	262	128 (48.8%)	134 (51.2%)		
>60	251	129 (51.4%)	122 (48.6%)		
Gender				1.858	0.173
Male	337	161 (47.7%)	176 (52.3%)		
Female	176	96 (54.6%)	80 (45.4%)		
Histologic grade				10.833	0.027^a
G1	12	5 (41.6%)	7 (58.4%)		
G2	219	121 (55.3%)	98 (44.7%)		
G3	201	99 (49.2%)	102 (50.8%)		
G4	73	26 (35.6%)	47 (64.4%)		
Gx	8	6 (75%)	2 (25%)		
Pathologic stage				16.331	0.001^a
Stage I	255	142 (55.7%)	113 (44.3%)		
Stage II	56	28 (50%)	28 (50%)		
Stage III	117	61 (52.2%)	56 (47.8%)		
Stage IV	82	25 (30.4%)	57 (69.6%)		
NA	3	1 (33.3%)	2 (66.7%)		
T stage				9.581	0.022^a
T1	261	145 (55.6%)	116 (44.4%)		
T2	68	32 (47%)	36 (52.9%)		
T3	173	78 (45%)	95 (55%)		
T4	11	2 (18.1%)	9 (81.9%)		
N stage				4.172	0.132 ^a
N0	229	116 (50.7%)	113 (49.3%)		
N1	16	4 (25%)	12 (75%)		
Nx	268	137 (51.2%)	131 (48.8%)		
M stage				35.724	< 0.001^a
M0	407	230 (56.6%)	177 (43.4%)		
M1	78	24 (30.7%)	54 (69.3%)		
Mx	28	3 (10.7%)	25 (89.3%)		
OS event				7.082	0.008
Alive	334	187 (54.4%)	157 (45.6%)		
Dead	169	70 (41.4%)	99 (58.6%)		
PFS event				6.775	0.009
No	353	191 (54.2%)	162 (45.8%)		
Yes	160	66 (41.2%)	94 (58.8%)		
DSS event				14.541	< 0.001
No	405	221 (54.6%)	184 (45.4%)		
Yes	108	36 (33.3%)	72 (66.7%)		

Statistical significance was determined by Chi-square test (if necessary, results were adjusted by Yate's correction) or Fisher's exact test (^a). OS: Overall survival; PFS: Progression free survival; DSS: Disease specific survival.